Less than three months after breaking cover with an impressive $102 million series A, Scorpion has whipped up another major funding round, nabbing $162 million for its next-gen cancer drugs.
Just over two months after announcing its debut with $108 million in funding, Boston startup Scorpion Therapeutics said Thursday it has raised an even larger amount of venture capital.
Whatever investors have peeped about Gary Glick and Keith Flaherty’s game plan to bring about Precision Oncology 2.0, it’s good enough for a $162 million infusion into Scorpion Therapeutics just weeks after its $108 million Series A.
When Gary Glick, Ph.D., left the CEO post at IFM Therapeutics, he didn’t know what was next. But he soon found himself on a plane with Loxo Oncology co-founder Keith Flaherty, and they got to talking about how they could “expand the boundaries of targeted oncology.”
Gary Glick is chief executive of Scorpion Therapeutics. Courtesy of Scorpion Therapeutics. Scorpion Therapeutics is the latest biotech to debut in Boston, with $108 million in venture capital and a roster of local industry veterans.
Just weeks before the pandemic hit the states, Gary Glick and Keith Flaherty had a chance to spend 12 hours together, talking craft and trade on...